Know Cancer

forgot password

Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform.

Open (Enrolling)
Spinal Muscular Atrophy, Neonatal Hyperbilirubinemia, Colon Cancer

Thank you

Trial Information

Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform.

Proximal spinal muscular atrophy is an autosomal recessive disorder with an overall
incidence of 1 in 10000 live births and a carrier frequency of 1 in 50. This severe
neuromuscular disease is characterized by a degeneration and loss of alpha motor neurons of
the spinal cord anterior horn cells, which results in progressive symmetrical weakness,
atrophy of the proximal voluntary muscles, and infant death. Here, we present a new, rapid,
simple and high reliable method to detect the SMN1 deletion and to determine the copy number
of the SMN1 and SMN2 by denaturing high-performance liquid chromatography (DHPLC). We
demonstrate that this assay is able to accurately distinguish 2 gene copies from 4 gene
copies and it can identify SMA carriers and normal populations by the accurate determination
of SMN copy number.

Fecal DNA testing is a promising tool for colorectal cancer screening. Researchers have
shown that DNA to be a good marker since it is stable in the stool; it shed continuously;
and, through the use of amplification tests, it can be detected in minute amounts. Many DNA
mutations associated with the process of colon cancer carcinogenesis have been
characterized. K-ras oncogene, adenomatous polyposis coli (APC), p53, and microsatellite
markers are examples of genes targeted as DNA markers in stool testing because they are
critical to the control of colorectal cell growth. Early clinical studies have shown that
multitarget DNA testing has a 71% to 91% sensitivity for detection of cancer and a 55% to
82% sensitivity for detecting adenoma 1cm or larger. We design this study, by using the
automated DHPLC analysis and the microsatellite markers set already at first, to stepwisely
set-up a high throughput but sensitive and specific screen method for colorectal cancer

Neonatal hyperbilirubinemia is a common problem and is of concern not only to pediatricians
but also to the parents of neonates. Two key enzymes, UDP-glucuronosyl transferase 1A1 and
heme oxygenase-1 (HO-1), that involve bilirubin metabolism are highly noticed. First, UGT1A1
is the key enzyme for bilirubin conjugation and mutations of UGT1A1 cause the unconjugated
hyperbilirubinemias known as Crigler-Najjar syndrome and Gilbert's syndrome. The high
allele-frequency of Gly71Arg and promoter polymorphism in UGT1A1 gene was found to be
responsible for neonatal hyperbilirubinemia without obvious cause. Second, HO-1 is a
rate-limiting enzyme in the heme metabolism and allows for the degradation of heme to
biliverdin. Recently, Maruo et al. demonstrated that (16/17) breastfed Japanese infants with
apparent prolonged jaundice had at least one mutation of the UGT1A1. These data suggested
that that defects of UGT1A1 may be an underlying cause of the prolonged unconjugated
hyperbilirubinemia associated with breast milk. However, to date the association between
breastfed infants with severe hyperbilirubinemia and UGT1A1 gene mutation is still unclear.
In this study, we will analyze the UGT1A1 and HO-1 genes of infants with unconjugated
hyperbilirubinemia associated with breast milk to ascertain whether genetic factors are

This project will contribute to apply DHPLC on establishing various novels, fast, and
reliable applications for diagnosis of SMA and carrier detection of SMN1 and SMN2 genes,
sensitive and specific screen method for colorectal cancer screen, and analyze the UGT1A1
and HO-1 genes of infants with unconjugated hyperbilirubinemia associated with breast milk.

Inclusion Criteria:

- Clinical diagnosis of Spinal muscular atrophy (SMA)

Exclusion Criteria:

- nil

Type of Study:


Study Design:

Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal, Time Perspective: Prospective

Principal Investigator

Yi-Ning Su, MD,PhD

Investigator Role:

Study Chair

Investigator Affiliation:

National Taiwan University Hospital


Taiwan: Department of Health

Study ID:




Start Date:

June 2004

Completion Date:

Related Keywords:

  • Spinal Muscular Atrophy
  • Neonatal Hyperbilirubinemia
  • Colon Cancer
  • Spinal muscular atrophy (SMA)
  • SMN1/SMN2 gene
  • denaturing high-performance liquid chromatography (DHPLC)
  • multiplex PCR
  • gene dose
  • carrier test
  • screen
  • stool
  • microsatellite
  • Colonic Neoplasms
  • Hyperbilirubinemia
  • Muscular Atrophy
  • Muscular Atrophy, Spinal
  • Atrophy
  • Hyperbilirubinemia, Neonatal